SCHEMBL1706855

SCHEMBL1706855

O=c1oc2cc(O)c(O)cc2cc1-c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PON1 P27169 1/20 0.72
NPC1 O15118 5/20 0.69
MIF P14174 2/20 0.69
GPR35 Q9HC97 2/20 0.68
RAB9A P51151 4/20 0.65
MAOB P27338 3/20 0.65
KDM4E B2RXH2 3/20 0.65
ALDH1A1 P00352 2/20 0.65
ADORA3 P0DMS8 3/20 0.62
ADORA2A P29274 3/20 0.62
ADORA1 P30542 3/20 0.62
PGR P06401 1/20 0.62
KMT2A Q03164 2/20 0.60
ESR2 Q92731 2/20 0.58
GAPDH P04406 2/20 0.58
ESR1 P03372 1/20 0.58
GAA P10253 1/20 0.58
HPGD P15428 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481314 0.84 NPC1 (0.61) PON1NPC1MIFGPR35RAB9A
SCHEMBL8118640 0.84 PON1 (0.73) PON1NPC1MIFGPR35RAB9A
SCHEMBL8117535 0.84 PON1 (0.73) PON1NPC1MIFGPR35RAB9A
SCHEMBL8121922 0.83 MIF (0.73) PON1NPC1MIFGPR35MAOB
SCHEMBL8117498 0.83 MAOB (0.67) PON1NPC1MIFGPR35RAB9A
SCHEMBL591688 0.82 MIF (1.00) NPC1MIFRAB9AMAOBKDM4E
SCHEMBL21761552 0.82 NPC1 (0.77) NPC1MIFRAB9AMAOBKDM4E
SCHEMBL28895384 0.82 KDM4E (0.62) PON1NPC1MIFGPR35RAB9A
SCHEMBL30051200 0.82 KDM4E (0.62) PON1NPC1MIFGPR35RAB9A
SCHEMBL28390166 0.81 GPR35 (1.00) NPC1MIFGPR35MAOBPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US claimed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US claimed
EP-2027279-B1 Phenolic compounds with cosmetic and therapeutic applications LIBRAGEN (FR) 2012-04-18 EP claimed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP claimed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO claimed
CN-105838758-B Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin 利布莱根公司 2020-03-06 CN disclosed
US-9828407-B2 Water soluble and activable phenolic derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives LIBRAGEN (FR) 2017-11-28 US disclosed
CN-105838758-A Water soluble phenolics derivatives with dermocosmetic and therapeutic applications 利布莱根公司 2016-08-10 CN disclosed
CN-101611148-B Water-soluble phenolic derivatives for cosmetic and therapeutic applications on the skin LIBRAGEN (FR) 2016-03-16 CN disclosed
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES LIBRAGEN (FR) 2014-03-27 US disclosed
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives LIBRAGEN (FR) 2009-09-17 US disclosed
EP-2027279-A2 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES Libragen (FR) 2009-02-25 EP disclosed
WO-2007144368-A2 WATER SOLUBLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS LIBRAGEN (FR) 2007-12-21 WO disclosed
EP-0645382-B1 COUMARIN DERIVATIVE AND USE THEREOF MORINAGA MILK INDUSTRY CO LTD (JP) 2000-07-12 EP disclosed
US-5574062-A COMPOUNDS HAVE 3-ARYL AND 7-HYDROXY OR -ACYLOXY; USE TO INHIBIT 12-LIPOXYGENASE MORINAGA MILK INDUSTRY CO., LTD. (JP) 1996-11-12 US disclosed
EP-0645382-A1 COUMARIN DERIVATIVE AND USE THEREOF MORINAGA MILK INDUSTRY CO., LTD. (JP) 1995-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233876-A1 Water Soluble and Activable Phenolics Derivatives with Dermocosmetic and Therapeutic Applications and Process for Preparing Said Derivatives UGGT1, TYR, LCT PON1 128/4885NPC1 1836/4885MIF 1663/4885
US-20140088030-A1 WATER SOLUBLE AND ACTIVABLE PHENOLICS DERIVATIVES WITH DERMOCOSMETIC AND THERAPEUTIC APPLICATIONS AND PROCESS FOR PREPARING SAID DERIVATIVES UGGT1, TYR, G6PD PON1 131/4885NPC1 2130/4885MIF 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.